Inify Laboratories has achieved a measurable impact in prostate cancer diagnostics. Official statistics from the Swedish Cancer Registry show that the company has shortened waiting times for prostate biopsies by several weeks for each patient since entering the market.
Fredrik Palm, CEO of Inify Laboratories, emphasised this achievement during a panel talk on the company’s second quarter, moderated by Olie Eikeland.
“It’s all about pathways. By supporting the entire clinical pathway for prostate cancer – from the urology department to the pathology department – we generate measurable efficiency and quality gains across the patient pathway, ultimately delivering faster and better care for every patient,” says Fredrik Palm.
This measurable impact is also reflected in the market, where Inify today holds an 80% share in the Stockholm region and around 15% nationally. With this strong position, Inify is taking a leading role in the development of modern diagnostics, focusing on measurable improvements across the entire patient pathway.
Across borders, Inify is making strong progress in establishing itself in the UK. A key breakthrough is the signing of a contract with its first UK customer, Parkside Suite – part of the Frimley NHS Foundation Trust – and the successful delivery of the first diagnostics for a UK patient. In parallel, construction of Inify’s brand-new laboratory is moving forward, to open as early as possible in 2026.
“We see a huge need for improvements in patient pathways in the United Kingdom. This milestone proves that we can already support UK healthcare with high-quality service from our Swedish laboratory – saving valuable time for both healthcare providers and patients, while preparing for a local presence,” says Fredrik Palm.
In the panel discussion, Fredrik Palm shares how Inify has achieved rapid impact in healthcare and diagnostics – and offers more on the upcoming UK lab, its capacity and location, as well as the development of gastrointestinal diagnostics and how it differs from prostate cancer diagnostics.
Listen to the full panel discussion here: Panel talk about Inify’s second quarter 2025